Ser10

Site Information
tTATMAtsGsArKRL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 14572318

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:	melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 5 ) , HeLa (cervical) ( 2 ) , HeLa_Meta (cervical) ( 4 ) , HeLa_Pro (cervical) ( 4 ) , HeLa_Telo (cervical) ( 4 ) , Jurkat (T lymphocyte) ( 6 ) , K562 (erythroid) ( 3 ) , WM239A (melanocyte) ( 1 )

Upstream Regulation
Treatments:	MG132_withdrawal ( 4 )

References
1	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
4	Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81 20097925 Curated Info
5	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
6	Possemato A (2008) CST Curation Set: 5316; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info